1. Introduction 2. GPL antigens of MAC 2-1. Chemical structure 2-2. Biologic roles of GPL 3. Development of serodiagnosis of active MAC pulmonary disease (PD) 3-1. Antigenic epitope: GPL core 3-2. Antibody class 3-3. Serodiagnosis of active MAC-PD proven by repeated sputum cultures 3-4. Serodiagnosis of active MAC-PD proven by bronchial wash culture using bronchoscopy 4. International collaboration studies of the serodiagnosis 5. Conclusions and future perspectives SUMMARY: Rapid and accurate diagnosis of infectious diseases, including mycobacterial disease such as tuberculosis (TB) and diseases due to nontuberculous mycobacteria (NTM), is a very important element of global health. The gold standard in diagnosis of mycobacterial diseases remains clinical examination, combined with direct microscopic examination of sputum and culture of bacteria. Culture of slowly growing mycobacteria, including Mycobacterium tuberculosis and NTM (such as M. avium complex: MAC), can take up to 4 to 6 weeks, and in 10-20z of cases the bacillus is not successfully cultivated. Diagnosis of MAC pulmonary disease (MAC-PD) is complicated and time-consuming (usually at least 1 month). I have characterized the nature of MAC antigens and immune responses from the aspect of basic mycobacteriology, and then translated to clinical science. My multicenter study in Japan has demonstrated the usefulness of a serodiagnostic test to determine serum IgA antibodies against mycobacterial glycopeptidolipid (GPL) core antigen for diagnosing MAC-PD within a few hours. To validate in a larger number of patients, at diverse geographic locations, and among other races, the test was also assessed the usefulness internationally in the United States and Taiwan. In this review, I discuss development of serodiagnosis of MAC-PD by translational research and international collaboration study.
Introduction
Mycobacterial diseases, such as tuberculosis (TB) and nontuberculous mycobacterial disease, continue to pose major public health challenges in developed, as well as developing, countries. Among mycobacterial diseases, pulmonary disease due to nontuberculous mycobacteria (NTM) has been increasing recently, although the incidence of TB has been falling worldwide for about a decade (1, 2) . In Japan and the United States of America (USA), Mycobacterium avium complex (MAC) accounts for approximately 70-80z as a causative agent of NTM disease (1,3). The annual incidence rate of NTM diseases per 100,000 people is approximately 6 in Japan (4). MAC is now widely recognized as an important pathogen that causes chronic and progressive pulmonary disease (PD) even in patients without human immunodeficiency virus (HIV) infection. The increasing incidence of MAC pulmonary disease (MAC-PD) makes its diagnosis and management a matter of increasing concern to respiratory physicians.
The diagnosis of MAC-PD is difficult because in contrast to Mycobacterium tuberculosis, MAC contamination of clinical specimens can come from environmental sources such as water, dust and soil, and it may colonizes the respiratory tract without any accompanying invasive disease (1) . The diagnosis rests on recovery of the pathogen from cultures, although sputum cultures positive for MAC do not in themselves prove infection because MAC may exist as saprophytes in the airway or as environmental contaminations. Thus, isolation of MAC from sputa is insufficient to document pulmonary infection. According to the guideline of the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) (1), the diagnosis of PD due to MAC is complicated and time-consuming. MAC is ubiquitous in nature and the diagnosis of MAC diseases is required for clinical and microbiologic findings, such as repeated isolation/ cultures of MAC from sputa (Table 1 ). In addition, it is also difficult to discriminate MAC-PD from infection due to other mycobacteria in the absence of culture results, because clinical features such as symptomatic or radiographic findings are very similar in mycobacterial GPL core is a common in all serotypes of mycobacteria possessing GPL indicated by broken lines ( ). do not meet the diagnostic criteria should be followed until the diagnosis is firmly established or excluded. 6. Making the diagnosis of NTM lung disease does not, per se, necessitate the initiation of therapy, which is decision based on potential risks and benefits of therapy for individual patients. diseases. There are no known instances of human-tohuman transmission of NTM and therefore the isolation of patients is unnecessary. From the aspect of infection control, it is particularly important to distinguish between MAC-PD and pulmonary TB. In light of the difficulties in obtaining a clear-cut diagnosis of MAC-PD, particularly given the propensity for this disease to afflict relatively elderly and frail patients, less invasive diagnostic methods are needed.
To overcome these difficulties, development of rapid, simple, noninvasive, and accurate methods to diagnose MAC disease is needed to control the disease. In this regard, serodiagnosis that differentiates TB and disease due to M. kansasii and MAC is required, because MAC, but not the majority of M. tuberculosis and M. kansasii, is resistant to most of the available anti-TB drugs (1). We have developed enzyme immunoassay (EIA) for serodiagnosis of active MAC disease using glycopeptidolipids (GPLs) that are the major and specific cell surface antigens of MAC. The EIA is approved by the Ministry of Health, Labour and Welfare of Japan and now commercially available in clinical use. In addition, it is also assessed internationally in USA and Taiwan. In this review, I discuss development of serodiagnosis of MAC-PD by translational research from basic mycobacteriology to clinic and international collaboration study to serodiagnose and control the disease.
2. GPL antigens of MAC 2-1. Chemical structure Figure 1 shows the features of major MAC antigen, GPL used in the immunoassay. The chemical structure of GPL is composed of a common GPL core, fatty acyl-
, and the different moiety of oligosaccharide linked at the Thr of the core (3, 5) . The core is composed of fatty acid, 3 amino acids, and rhamnose. GPLs are the major and specific cell surface antigens of the MAC and M. scrofulaceum group, and they can be subdivided into 31 distinct serotypes based on the oligosaccharide. The approximate MW of GPL core is 1.2 kilodalton (5-7).
Besides MAC, M. scrofulaceum, M. chelonae, M. abscessus, and M. fortuitum also possess GPL antigens in their cell walls (3, 5, 8) . Because M. chelonae, M. abscessus, and M. fortuitum are rapidly growing mycobacteria, diseases due to such mycobacteria are rapidly diagnosed. By contrast, slowly growing M. kansasii and M. tuberculosis complex, including BCG, do not have GPL (Table 2) .
2-2. Biologic roles of GPL
GPL is involved in colony morphology, hydrophobicity and biofilm formation of the bacterium (3). In the infected host, GPL prevents phagocytosis by macrophages, inhibits phagosome-lysosome fusion, and cytokine production via through toll-like receptor (TLR) 2 pathway. Thus, GPL exerts a pleiotropic activity on both bacteria and hosts (3,7).
Development of serodiagnosis of active MAC-PD
3-1. Antigenic epitope: GPL core My early study of the serodiagnosis, I used a mixture of GPL antigens derived from 11 distinct serotypes of MAC (8) . However, there are problems with the transition of the assay from a research tool to widespread clinical use. Specifically, the preparation of GPL anti- gen that is of a consistent quality, as well as quantity, from 11 reference strains of MAC is both time-and cost-consuming. Identification of a simple and stable antigen for use in serodiagnostic tests for MAC disease is necessary. The titers of GPL antibody were reduced to background levels by adding GPL core antigens and antibody activity was absorbed by them. As a result, the immunodominant epitope is GPL core (9) , which is common in all serotypes of mycobacteria possessing GPL.
3-2. Antibody class
From the aspect of sensitivity and specificity of EIA detecting serum antibodies specific for MAC-GPL, I next determined antibody class, such as IgG, IgA, and IgM. The respective sensitivities and specificities of GPL core-based EIA for diagnosis of MAC-PD were 72.6z and 92.2z for IgG, 92.5z and 95.1z for IgA, and 78.3z and 91.0z for IgM when compared to the gold standard, the diagnostic criteria of ATS and IDSA (1) ( Table 1 ). The best sensitivity and specificity for the diagnosis of MAC-PD was obtained by measuring IgA antibodies against GPL core (9).
3-3. Serodiagnosis of active MAC-PD proven by repeated sputum cultures My colleagues and I have attempted the serodiagnosis of active MAC-PD, when compared to MAC contamination, TB, NTM diseases (M. kansasii and M. fortuitum) rather than MAC, other lung diseases including chronic obstructive pulmonary disease, interstitial pneumonia, cancer, bacterial pneumonia and sarcoidosis, and healthy subjects (10, 11) . A six-institution multicenter study has demonstrated sensitivity; 84z and specificity; 100z for the serodiagnosis of active MAC-PD (11) proven by repeated sputum cultures when cut-off level of IgA antibody against GPL core was set at 0.7 U/ml (Figure 2 ). The serodiagnosis can differentiate MAC disease from disease due to M. kansasii, MAC contamination, TB, chronic obstructive pulmonary disease, interstitial pneumonia, cancer, bacterial pneumonia and sarcoidosis, but not disease caused by M. fortuitum possessing GPL (12).
3-4. Serodiagnosis of active MAC-PD proven by
bronchial wash culture using bronchoscopy MAC-PD is usually diagnosed according to the guidelines set forth by the ATS/IDSA, which include clinical and microbiological criteria (1), as mentioned previously. Bronchoscopy to obtain bronchial wash for culture is often considered in patients in whom MAC-PD is difficult to diagnose by routine sputum examination; however, it is difficult to perform bronchoscopy in all patients, because bronchoscopy is invasive. In light of the difficulties in obtaining a clear-cut diagnosis of MAC-PD, particularly given the propensity for this disease to afflict relatively elderly and frail patients, less invasive diagnostic methods are needed. The novel approach to help diagnose such cases has been needed. I have demonstrated sensitivity; 79z and specificity; 96z using the serodiagnosis for active MAC-PD proven by bronchial wash culture (12) . The result indicates the availability of serodiagnosis of MAC disease proven by bronchoscopy, although both sensitivity and specificity were slightly low when compared to such disease with sputum-positive MAC-PD.
International collaboration studies of the serodiagnosis
Obviously the serodiagnosis by EIA requires validation in a larger number of patients, at diverse geographic locations, and among other races. To extend the usefulness of EIA kit for MAC-GPL internationally, I have compared cut-off level, sensitivity and specificity among Japan, USA, and Taiwan (Table 3 ). The performance in Taiwan (sensitivity: 61z, specificity: 91z) (13) was relatively low when compared to Japan (sensitivity: 84z, specificity: 100z) (11) and USA (sensitivity: 77z, specificity: 94z) (14) . Possible reasons for low sensitivity and specificity in Taiwan include relatively high incidence of diseases due to rapidly growing mycobacteria possessing GPL and study population contains immunocompromised hosts, although studies in Japan and USA employed sera of patients with im- munocompetent MAC-PD. Similarly relatively low sensitivity (77.5z) obtained from the South Korea in where disease due to rapidly growing mycobacteria possessing GPL was common (15) , although the serodiagnostic performance differentiating MAC-PD and TB is high (100z). I used the cut-off value at 0.7 U/mL in both Japan (11) and Taiwan (13), but 0.3 U/mL was set in the USA (14) based on the best performance calculated by the receiver operating characteristic curve obtained each study. As a result, the cut-off value in the US was low compared to Japan and Taiwan.
Conclusions and future perspectives
My colleagues and I have developed a promising, rapid, noninvasive test that has potential to aid in deciding whether or not a sputum smear containing acid fast bacilli is due to TB, contamination, or MAC. The EIA kit (Capilia MAC Ab ELISA  , TAUNS Laboratories, Shizuoka, Japan) for serodiagnosis of active MAC disease has become commercially available for clinical use in Japan. Besides active MAC-PD, the test requires availability in extrapulmonary MAC disease, latent MAC infection and hypersensitivity lung disease (hot tub lung disease) due to MAC. Hopefully the test will be included in official diagnostic criteria of ATS/IDSA in the near future. Consequently, the serodiagnosis by detecting serum antibodies to MAC-GPL helps control the disease. 
